Futu Holdings Ltd vs Guardant Health Inc. Common Stock — how do they compare? Futu Holdings Ltd trades at $110.07 (market cap $15.25B), while Guardant Health Inc. Common Stock trades at $165.58 (market cap $22.58B). The key difference: Guardant Health Inc. Common Stock is the larger of the two by market cap, and Futu Holdings Ltd pays a 2.39% dividend while Guardant Health Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Futu Holdings Ltd for 34 Days and Guardant Health Inc. Common Stock for 0 Days on average.
| FUTU | GH | |
|---|---|---|
Market Cap | $15.25B | $22.58B |
Volume | 812,567 | 2,200,599 |
Sector | Financials | Health |
52-Week High | $199.04 | $187.22 |
52-Week Low | $89.76 | $61.73 |
Typical Hold Time | 34 Days | 0 Days |
Enterprise Value | $15.59B | $23.22B |
Dividend Yield | 2.39% | — |
Signals from Pluang's Aura AI — not financial advice
Futu Holdings (FUTU) trades at $109.68, down 3.12% today, amid a bearish technical signal but strong fundamentals. Revenue grew to $22.85B in 2025 with a net income margin of 49.62%, while valuation ratios like a P/E of 10.95 suggest potential undervaluation. Recent news includes Moomoo's partnership with X and a class action lawsuit deadline, adding mixed sentiment.
The outlook is cautiously optimistic due to robust earnings growth and analyst upside targets near 33%, but risks from legal issues and competitive pressures warrant monitoring. Investors may find value if the company executes on overseas expansion, though volatility from technical bearishness persists.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →Guardant Health develops blood tests for cancer care. Its tests support genomic profiling, cancer screening, recurrence monitoring, and treatment decisions.
Read more on GH →